



GRAFTYS strengthens its management and operations

Aix-en-Provence, March 31st, 2016 - Graftys, a French Société Anonyme specialized in the development, manufacturing and commercialization of synthetic orthopedic biomaterials, announced today the appointment of its Chairman of the Board, Gilles Alberici, as Chief Executive Officer, effective January 20, 2016. Aurélien Valet has been appointed deputy CEO.

“It is a very exciting challenge for me to guide Graftys and build an integrated platform in synthetic orthopedic biomaterials.” indicated Gilles Alberici. “We will focus our efforts on short and mid-term R&D projects to develop new business opportunities and scientific partnerships. Graftys has built a solid commercial foundation through the excellent reputation of our marketed products, and we currently sell in 25 countries via various partnerships, including Arthrex and Smith & Nephew. In addition, Graftys’ pipeline contains promising and patented R&D projects for both orthopedics and spine. We plan to leverage our research and development through enhanced relationships with our academic partners, and to accelerate time-to-market, increase our commercial revenues.”

“Gilles’ leadership and entrepreneurial experience will help Graftys to transition from an integrated manufacturer of calcium phosphate cements into a focused company, bringing innovative products to market, and offering solutions to orthopedic surgeons and patients” commented Aurélien Valet, deputy CEO and co-founder of Graftys. “Gilles has been at Graftys since 2009, first as a non-executive Director, then as our Chairman of the Board. We place a lot of trust in him and the Graftys team is very pleased by the new organization we have set up. We will build on our hybrid business model, combining development and revenue generation”.

The main initial tasks for the management team will be to strengthen the visibility of Graftys within the orthopedic community, and continue to develop Graftys through its pipeline of products and projects. In particular, Graftys will invest in the development of GRFT-M03, cement with unprecedented osteogenic properties to be mixed with autologous blood.

Gilles Alberici, PharmD, PhD has 30 years of experience in the European pharma and biotech industry, and is the founder of several biopharmaceutical companies: IMTIX (1994), a transplantation company, OPi (2000), a company dedicated to rare and severe diseases, which was acquired in 2007, Orega Biotech (2010), an early stage biotechnology company. Gilles Alberici set up *initiative* Octalfa in 2006, a family-owned and independent investment company specializing in early-stage operations in life sciences. Octalfa has been a Graftys shareholder since 2009.

Alongside with its investments, Octalfa manages the Dominique & Tom Alberici-Octalfa Corporate Foundation, to support projects aiming at improving the care of cancer patients and disabled people. More than 70 projects in France and Madagascar have been financed to date.

About Graftys

Founded in 2005, Graftys is based in Aix-en-Provence and Nantes (France), with a US office in Chicago. The company develops, manufactures and markets synthetic bioactive orthopedic biomaterials. Graftys technologies provide innovative therapeutic products in bone tissue engineering for unmet medical needs. The company partners with leading research institutions in France and is the licensee or the co-owner of 8 patent families. Graftys has received FDA clearance for three 510(k) applications with its calcium phosphate materials, which are also CE marked. Graftys products address various indications in orthopedics, traumatology, spine and dental. Graftys markets its range of products in over 25 countries, including the United States, through distribution partnerships.

For further information: <http://www.graftys.com>

Contact : news@graftys.fr